OSA-Direct
Tuesday, 11 Dec 2018

E Ink, HTC and Palladio collaborate to develop smart label for IoT-based healthcare services

The collaborations aims to enable real-time medication consumption tracking, symptom and side effects disclosure, and treatment outcome evaluation

4 Oct 2016 | Editor

E Ink Holdings (E Ink), HTC Healthcare, and Palladio Group, have announced a collaboration to improve medication adherence by harnessing the healthcare segment of the Internet of Things (IoT).

The announcement said that medication nonadherence is a common, complex and costly problem that contributes to poor patient outcomes and dwindling healthcare resources.

Nonadherence is difficult to measure precisely and, to date, interventions to mitigate it have been largely unsuccessful. Using smartphone applications together with IoT-based smart devices provides a new approach to improving medication adherence.

Patient adherence can apply to several different clinical trial situations for example - adherence to study procedures, study visit compliance, medications and adverse event reporting.

In fact, medication nonadherence during a clinical trial can result in increased clinical trial cost, as well as impacts to regulatory dosing recommendations upon medical product approval.

To combat this prevalent problem, E Ink created a smartphone-based smart packaging label that displays personalised content that can be pushed to the packaging label as a communication interface, delivering vital information to patients and creating a gateway to improve patient engagement.

Patients can receive information, including:

  • A reminder that it’s time for users to take their medication
  • The quantity of medication in the package
  • The time at which medication is taken

Further, patients have the ability to provide refill service by simply pushing a button on the product label.

Developing a privacy-preserving medication management software, HTC will enable real-time medication consumption tracking, symptom and side effects disclosure, and treatment outcome evaluation.

Patients are able to get detailed information about their health status via two-way communication with the care team (composed of physicians, case managers, and pharmacists) and to refill their prescription via the platform.

Dr. FY Gan, General Manager of ESI Business Unit of E Ink Holdings, said, "E Ink's smart packaging label can be applied on both primary and secondary containers, from paperboard cartons to prefilled syringes to pill dispensers." Dr. FY Gan, added, "This readily available technology offers many features designed to help patients and healthcare providers improve medication-taking behaviors."
Dr. Edward Chang, president of HTC Healthcare, said "Our artificial intelligence technology is the backbone of the platform, aiming to improve treatment effectiveness and, eventually, a personalized medication solution in the near future."
Mauro Marchi, CEO of Palladio Group, said, "As a packaging and services provider fully dedicated to the pharmaceutical industry, we are committed to developing the most successful applications with our partners. 'PhutureMed' is an example of a program that has been conceived with the main objective of creating innovative packaging solutions for the medicine of the future. It’s an intelligent packaging system designed to support patients in monitoring and complying with their medicine regimes."

           


About E Ink

Founded in 1992 by Taiwan's leading papermaking and printing group YFY, E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences, and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications. Its EPD products make it the worldwide leader for ePaper. Its FFS technologies are a standard for high end consumer electronic products. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of displays to the eReader market.

Source: E Ink

About HTC Corp

HTC Corp, founded in 1997, manufactures smartphones and was ranked as a top brand in the world by Interbrand’s Best Global Brands report. HTC brings brilliance to life by continuing to create technology that can address society’s toughest challenges. Since 2014, HTC has partnered with Taiwanese and US physicians, scientists, and engineers who recognize the dire need for healthcare improvement around the world. HTC is participating in the $10 million Qualcomm Tricorder XPRIZE competition, which aims to foster disruptive revolution in healthcare by stimulating the development of innovative personal diagnostic devices. As of August 27, 2014, HTC was one of the top 10 finalist teams in the competition. In 2015, HTC developed a new healthcare business unit, to deliver direct patient care that includes a symptom checker, a medication manager, and telehealth. HTC believes that artificial intelligence can bring huge benefits to medical research and aims to help clinicians provide faster, better treatments to their patients by utilizing advanced technology to analyze accumulated medical data.

Source: HTC Corp

About Palladio Group

Palladio Group is the result of a long and successful process started in Italy, 70 years ago. Palladio is the Leader for the Secondary Packaging Supplier and Service Provider for the Healthcare and Cosmetic Industry in Italy and one of the most interesting and dynamic companies in the International market. With its plants located in Italy, Ireland, Serbia, and Russia (opening soon) produce folding cartons, leaflets, booklets, labels and printed alu-foil for the largest pharma and cosmetic companies worldwide. Palladio is continually making a constant effort to improve, by offering innovative technological solutions and advanced concepts and services towards patient compliance to therapy. Our optimum standards aim for nothing short of excellence, with a continuous effort to innovation and the total sustainability of all our processes.

Source: Palladio Group